<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556465</url>
  </required_header>
  <id_info>
    <org_study_id>3046</org_study_id>
    <nct_id>NCT00556465</nct_id>
  </id_info>
  <brief_title>Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy</brief_title>
  <official_title>Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic nephropathy has become the single most frequent cause of end-stage renal disease.&#xD;
&#xD;
      On a molecular level, at least five major pathways have been implicated in glucose-mediated&#xD;
      vascular and renal damage and all of these could reflect a single hyperglycaemia-induced&#xD;
      process of overproduction of reactive oxygen species.&#xD;
&#xD;
      Recent studies have shown that inflammation, and more specifically pro-inflammatory cytokines&#xD;
      play a determinant role in the development of micro- vascular diabetic complications, most of&#xD;
      the attention has been focused on the implications of TNF-Î± in the setting of diabetic&#xD;
      nephropathy.&#xD;
&#xD;
      Glutathione is the most abundant low-molecular-weight thiol, and Glutathione/ glutathione&#xD;
      disulfide is the major redox couple in animal cells.&#xD;
&#xD;
      N-acetylcysteine is effective precursors of cysteine for tissue Glutathione synthesis.&#xD;
&#xD;
      Not only does N-acetylcysteine exhibit antioxidant properties, but it may also counteract the&#xD;
      glycation cascade through the inhibition of oxidation.&#xD;
&#xD;
      N-acetylcysteine can also reduce the apoptosis elicited by reactive oxygen species .&#xD;
&#xD;
      Indeed, N-acetylcysteine has been shown to inhibit reactive oxygen species induced mesangial&#xD;
      apoptosis and to be able to protect cells from glucose-induced inhibition of proliferation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure,serum creatinine,GFR,c-reactive protein,</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>A, 1,III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm patients took 1200 mg N-acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B,2, III</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600 mg of effervescent N-acetylcysteine tablet twice per day for three months</description>
    <arm_group_label>A, 1,III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients with more than 500 mg protein in 24 hours urine protein sample&#xD;
&#xD;
          -  Males and post-menopausal non-lactating and non-pregnant females.&#xD;
&#xD;
          -  Age greater than or equal to 30 years of age.&#xD;
&#xD;
          -  Serum creatinine less than 3.0 mg/dL (265 micromoles per liter)&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 (insulin-dependent; juvenile onset) diabetes&#xD;
&#xD;
          -  Patients with known non-diabetic renal disease&#xD;
&#xD;
          -  Renal allograft&#xD;
&#xD;
          -  Myocardial infarction, coronary artery bypass graft surgery, or percutaneous&#xD;
             transluminal coronary angioplasty/stent within 3 months of study entry&#xD;
&#xD;
          -  Cerebrovascular accident within 3 months of study entry&#xD;
&#xD;
          -  New York Heart Association Functional Class III or IV&#xD;
&#xD;
          -  Known allergies or intolerance to N-acetylcysteine&#xD;
&#xD;
          -  Untreated urinary tract infection or other medical condition that may impact urine&#xD;
             protein values.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohammad mahdi sagheb, MD</last_name>
    <role>Study Director</role>
    <affiliation>shiraz university of medical science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mohammad mahdi sagheb</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>0098711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>November 9, 2007</last_update_submitted>
  <last_update_submitted_qc>November 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2007</last_update_posted>
  <keyword>diabetic nephropathy</keyword>
  <keyword>proteinuria</keyword>
  <keyword>antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

